Scarica l'app Stockscreener
2.45
1.61%
-0.04
Dopo l'orario di chiusura:
2.52
0.07
+2.86%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché IBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.49
Aprire:
$2.53
Volume 24 ore:
1.17M
Relative Volume:
0.22
Capitalizzazione di mercato:
$84.63M
Reddito:
$300.00K
Utile/perdita netta:
$-24.74M
Rapporto P/E:
-2.4354
EPS:
-1.006
Flusso di cassa netto:
$-19.19M
1 W Prestazione:
-6.13%
1M Prestazione:
+10.36%
6M Prestazione:
+162.45%
1 anno Prestazione:
-52.24%
Intervallo 1D:
$2.38
$2.745
Intervallo di 1 settimana:
$2.31
$2.745
Portata 52W:
$0.5562
$5.60
iBio Inc Stock (IBIO) Company Profile
Nome
iBio Inc
Settore
Industria
Telefono
302-355-0650
Indirizzo
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
2.45 | 84.63M | 300.00K | -24.74M | -19.19M | -1.006 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Oppenheimer | Outperform |
| 2025-10-17 | Iniziato | Leerink Partners | Outperform |
| 2024-05-28 | Iniziato | Chardan Capital Markets | Buy |
| 2021-11-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-01-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Iniziato | Alliance Global Partners | Buy |
Mostra tutto
iBio Inc Borsa (IBIO) Ultime notizie
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Highs Report: Is iBio Inc a turnaround storyRate Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
IBIO: Advancing novel antibody therapies for obesity and cardiometabolic disease with strong clinical momentum - TradingView
Jones Trading reiterates iBio stock rating on obesity drug data - Investing.com
iBio Reports Promising Preclinical Results for IBIO-610 Activin E Antibody in Fat-Selective Weight Loss for Obesity and Cardiometabolic Diseases 1 - Minichart
iBio reports fat reduction in primate obesity study - Investing.com Nigeria
iBio reports fat reduction in primate obesity study By Investing.com - Investing.com Australia
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential - TipRanks
iBio (IBIO) Reports Promising Preclinical Results for Obesity Tr - GuruFocus
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss - Bitget
Primate obesity study backs iBio fat-loss antibody, twice-yearly dosing potential - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Cash per share of iBio, Inc. – MUN:0JV0 - TradingView
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
iBio (NASDAQ:IBIO) Upgraded by JonesTrading to Strong-Buy Rating - MarketBeat
Jones Trading Initiates Coverage of iBio (IBIO) with Buy Recommendation - Nasdaq
JonesTrading Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
iBio (IBIO) Receives New 'Buy' Rating from Jones Trading | IBIO Stock News - GuruFocus
iBio (NYSE:IBIO) Now Covered by Analysts at JonesTrading - MarketBeat
Jones Trading initiates iBio stock with buy rating on obesity platform - Investing.com Australia
Jones Trading initiates iBio stock with buy rating on obesity platform By Investing.com - Investing.com South Africa
Ibio SEC Filings - Stock Titan
Revenue per share of iBio, Inc. – MUN:0JV0 - TradingView
iBio (NASDAQ:IBIO) Raised to Hold at Wall Street Zen - MarketBeat
IBio enters open market sale agreement with Jefferies - marketscreener.com
IBio Files $200 Million Mixed Shelf Offering - marketscreener.com
iBio Launches Up to $100 Million ATM Program With Jefferies to Bolster Liquidity - TradingView
iBio (NYSE: IBIO) launches $100M at-the-market stock offering with Jefferies - Stock Titan
IBio Inc files for mixed shelf of up to $200 million - marketscreener.com
iBio Inc Files For Mixed Shelf Of Upto $200 Million - TradingView
Ken Johnson - Crain's Chicago Business
IBIO: Pipeline advances in obesity and cardiovascular drugs with strong financial backing and near-term data - TradingView
IBIO: Advancing next-gen obesity therapies with strong financials and key data readouts ahead - TradingView
Growth Report: Will iBio Inc benefit from green energy policiesMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
LifeSci Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Aug Selloffs: Is Beazer Homes USA Inc forming a breakout patternTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
iBio (NYSEMKT:IBIO) Stock Price Up 2.9%Should You Buy? - MarketBeat
How do insiders feel about iBio Inc.Rate Cut & Step-by-Step Swing Trade Plans - mfd.ru
iBio to Participate in Upcoming Investor Conferences - The Manila Times
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
IBio, Inc. (IBIO) Stock: Price Predictions & Analysis - thedetroitbureau.com
ADAR1 discloses 4.4% iBio (IBIO) ownership in updated 13G filing - Stock Titan
Brookline Cap M Weighs in on iBio's Q3 Earnings (NYSE:IBIO) - MarketBeat
IBIO PE Ratio & Valuation, Is IBIO Overvalued - Intellectia AI
iBio (NASDAQ:IBIO) Rating Lowered to Sell at Wall Street Zen - MarketBeat
IBIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IBIO Should I Buy - Intellectia AI
Stock Recap: Will iBio Inc outperform its industry peersJuly 2025 Snapshot & Accurate Buy Signal Notifications - baoquankhu1.vn
IBIO: Chardan Capital Maintains 'Buy' Rating with Steady Price T - GuruFocus
iBio's (IBIO) Buy Rating Reiterated at Chardan Capital - MarketBeat
Can iBio Inc. stock attract ESG capital inflows2025 Fundamental Recap & Low Risk Entry Point Guides - mfd.ru
iBio Inc Azioni (IBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):